^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
Published date:
05/01/2022
Excerpt:
Patients with KRAS mutations showed a lower CBR (12.5% vs. 58.8%), shorter PFS (2.02 vs. 6.80 months) and OS (10.53 vs. 13.13 months)....Anlotinib combined with TQB2450 showed promising efficacy and was well tolerated in advanced BTCs. KRAS mutation and high TMB might serve as predictors of treatment efficacy.
DOI:
10.1002/hep.32548
